• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email
    SC 13G 1 b81067919.htm SCHEDULE 13G



     
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     
     
     
     
    Eupraxia Pharmaceuticals Inc.
         
         
    (Name of Issuer)
     
     
    Common Shares
         
         
     
    (Title of Class of Securities)
     
     
    29842P105
         
         
     
    (CUSIP Number)
     
     
    September 30, 2024
         
         
    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    □              Rule 13d-1(b)
    □              Rule 13d-1(c)
    ☒             Rule 13d-1(d)
     
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     



    CUSIP No. 29842P105
    SCHEDULE 13G
    Page 2 of 5 Pages




    1
    NAMES OF REPORTING PERSONS
     
    Robert Disbrow
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,092,500 (1)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,092,500 (1)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    3,092,500 (1)
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.6% (1) (2)
    12
    TYPE OF REPORTING PERSON
     
    IN
    (1) Includes (a) 2,592,500 shares of the Issuer’s (as defined below) common shares, with no par value (the “Common Shares”) and 200,000 Common Shares underlying Issuer’s Series 1 preferred shares, with no par value (the “Preferred Shares”) jointly owned by Robert Disbrow and Kim Kawaguchi, husband and wife (the “Disbrows”); and (b) 300,000 Common Shares held by the children of the Disbrows. The Disbrows disclaim beneficial ownership of the Common Shares held by their children.
    (2) Calculated based on the Common Shares and Preferred Shares, beneficially owned by the Reporting Person relative to the Issuer’s 35,622,553 outstanding Common Shares, as of June 30, 2024, as reported in the Issuer’s Form 6-K filed with the SEC on August 7, 2024, plus the 200,000 Preferred Shares.




    Item 1(a)
    Name of Issuer:
       
     
    Eupraxia Pharmaceuticals Inc.
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
       
     
    201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5GR.
       
    Items 2(a)
    Name of Person Filing:
       
     
    This Schedule 13G is being filed by Robert Disbrow (the “Reporting Person”).
       
    Item 2(b)
    Address of Principal Business Office:
     
    The business address of the  Reporting Person is:
     
    200 Burrard Street, Suite 700
     
    Vancouver, BC V6C 3L6
       
    Item 2(c)
    Citizenship:
       
     
    Robert Disbrow is a citizen of Canada.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Common shares, with no par value (“Common Shares”)
       
    Item 2(e)
    CUSIP Number:
       
     
    29842P105
       
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:
       
     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Act;
     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act;
     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act;
     
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
     
    (e)
    ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
    (f)
    ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     
    (g)
    ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
     
    (j)
    ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
     
    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).


     



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Select Reporting Person and is incorporated herein by reference for each such Select Reporting Person.
       
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    If this statement is being filed to report the fact that as of the date hereof a reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐ .
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    N/A
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
     
    N/A
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    N/A
       
    Item 9
    Notice of Dissolution of Group:
       
     
    N/A
       
    Item 10
    Certification:
       
     
    N/A
       
       


    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
     
     
     
    Dated: November 14, 2024
     
       /s/ Robert Disbrow
     
    Robert Disbrow






    Get the next $EPRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    7/24/2025$11.00Overweight
    Cantor Fitzgerald
    6/26/2025$12.00Buy
    H.C. Wainwright
    6/16/2025Speculative Buy
    Canaccord Genuity
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peterson Capital Hosts Canada Growth Conference in Ireland

    DUBLIN, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Seven of Canada's fastest growing public companies will be gathering outside of Dublin today as they kick off the third Canada Growth Conference hosted by Edmonton-based capital markets advisory firm Peterson Capital. More than fifty public company CEOs, Investment Advisors, fund managers and family offices will meet at the Powerscourt Hotel Resort from Thursday evening, September 25th to Saturday noon, September 27th  for presentations, informal receptions, meetings and social gatherings designed to highlight the opportunities that each of the public companies offers to potential investors. "We've held two conferences with the exact same fo

    9/25/25 2:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

    VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 14,636,363 common shares of the Company (the "Common Shares"), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$5.50 per Common Share for gross proceeds of approx

    9/24/25 8:54:51 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

    VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the "Offering") of 12,727,273 common shares of the Company (the "Common Shares") at a price to the public of US$5.50 per Common Share for gross proceeds of approximately US$70 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the O

    9/22/25 10:42:29 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $EPRX
    SEC Filings

    View All

    Cantor Fitzgerald initiated coverage on Eupraxia Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

    7/24/25 7:27:25 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    H.C. Wainwright initiated coverage on Eupraxia Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/26/25 8:10:08 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Canaccord Genuity initiated coverage on Eupraxia Pharmaceuticals

    Canaccord Genuity initiated coverage of Eupraxia Pharmaceuticals with a rating of Speculative Buy

    6/16/25 11:20:22 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    9/24/25 11:12:31 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SUPPL filed by Eupraxia Pharmaceuticals Inc.

    SUPPL - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    9/23/25 3:54:22 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    9/23/25 3:51:58 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Financials

    Live finance-specific insights

    View All

    Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis ("EoE")Additional data from cohorts 5–8 from Phase 1b/2a available in October 2025 VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with

    8/12/25 4:25:54 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

    Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

    5/6/25 6:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

    VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

    3/20/25 5:30:48 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eupraxia Pharmaceuticals Announces CFO Succession

    -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

    2/18/25 7:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

    VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

    10/31/24 7:36:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

    SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/7/24 4:10:15 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care